CY1107607T1 - Νουκλεοπρωτεϊνη ιου toscana - Google Patents

Νουκλεοπρωτεϊνη ιου toscana

Info

Publication number
CY1107607T1
CY1107607T1 CY20071101586T CY071101586T CY1107607T1 CY 1107607 T1 CY1107607 T1 CY 1107607T1 CY 20071101586 T CY20071101586 T CY 20071101586T CY 071101586 T CY071101586 T CY 071101586T CY 1107607 T1 CY1107607 T1 CY 1107607T1
Authority
CY
Cyprus
Prior art keywords
toscana
nuclear protein
toscana virus
induce
humoral
Prior art date
Application number
CY20071101586T
Other languages
English (en)
Inventor
Maria Grazia Cusi
Marcello Valassina
Pier Egisto Valensin
Original Assignee
Universita Degli Studi Di Siena
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita Degli Studi Di Siena filed Critical Universita Degli Studi Di Siena
Publication of CY1107607T1 publication Critical patent/CY1107607T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/12011Bunyaviridae
    • C12N2760/12022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/12011Bunyaviridae
    • C12N2760/12034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Αναπάντεχα, έχει ανακαλυφθεί ότι κεντρική πρωτεΐνη αντιγόνο του ιού TOSCANA μπορεί να επάγει μία προστατευτική χυμική απόκριση. Η εφεύρεση σχετίζεται με συνθέσεις που περιλαμβάνουν νουκλεπρωτεΐνη ιού Toscana. Αυτές μπορούν να χρησιμοποιηθούν στην θεραπεία ή στην προφύλαξη μόλυνσης από ιό Toscana. Eπίσης παρέχεται η χρήση του εσωτερικού ιικού αντιγόνου στην κατασκευή φαρμάκου για πρόκληση εξουδετεροποιητικής χυμικής αντι-ιικής ανοσολογικής απόκρισης.
CY20071101586T 1999-12-16 2007-12-14 Νουκλεοπρωτεϊνη ιου toscana CY1107607T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9929783.0A GB9929783D0 (en) 1999-12-16 1999-12-16 Toscana virus nucleoprotein
EP00987600A EP1237571B1 (en) 1999-12-16 2000-12-18 Toscana virus nucleoprotein

Publications (1)

Publication Number Publication Date
CY1107607T1 true CY1107607T1 (el) 2013-03-13

Family

ID=10866464

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101586T CY1107607T1 (el) 1999-12-16 2007-12-14 Νουκλεοπρωτεϊνη ιου toscana

Country Status (10)

Country Link
EP (1) EP1237571B1 (el)
AT (1) ATE374040T1 (el)
AU (1) AU2390101A (el)
CY (1) CY1107607T1 (el)
DE (1) DE60036563T2 (el)
DK (1) DK1237571T3 (el)
ES (1) ES2293934T3 (el)
GB (1) GB9929783D0 (el)
PT (1) PT1237571E (el)
WO (1) WO2001044288A2 (el)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298423A (en) * 1987-11-25 1994-03-29 The United States Of America As Represented By The Secretary Of The Army Nucleotide sequences encoding the expression of a Hantaan virus nucleocapsid protein and G1 and G2 glycoproteins
ITMI980889A1 (it) * 1998-04-24 1999-10-24 Diesse Diagnostica Nucleoproteina ricombinante del virus toscana

Also Published As

Publication number Publication date
PT1237571E (pt) 2007-12-31
WO2001044288A3 (en) 2002-01-24
WO2001044288A2 (en) 2001-06-21
EP1237571B1 (en) 2007-09-26
GB9929783D0 (en) 2000-02-09
DK1237571T3 (da) 2008-01-02
ATE374040T1 (de) 2007-10-15
AU2390101A (en) 2001-06-25
EP1237571A2 (en) 2002-09-11
ES2293934T3 (es) 2008-04-01
DE60036563D1 (de) 2007-11-08
DE60036563T2 (de) 2008-07-17

Similar Documents

Publication Publication Date Title
Dietzschold et al. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
MXPA02007413A (es) Vacuna para la inmunizacion profilactica o terapeutica contra el vih.
BR0113822A (pt) Vacina
HUP0202804A2 (hu) Új készítmény
BR0116026A (pt) Imidazoquinolinas substituìdas por tioéter
EA200600865A1 (ru) Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью
ATE345389T1 (de) Immunologisch relevante antigene aus herpes simplexvirus
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
ES2187530T3 (es) Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
ATE401392T1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
TR200102024T2 (tr) Yeni tedavi.
PT777669E (pt) Utilizacao de succinato de 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral
CY1107607T1 (el) Νουκλεοπρωτεϊνη ιου toscana
DK1476467T3 (da) IgG3-immunglobulin som beskyttelsesmarkör mod virusinfektionssygdomme og anvendelser deraf
DE69320469D1 (de) Behandlung von herpesvirus infektion
SE9702242D0 (sv) Vaccine compositions V
DK0685235T3 (da) Ekstrakter af Piliostigma thonningii, anvendelse heraf og formuleringer, som indeholder dem
DE69130571D1 (de) Peptide, die infektionen mit menschlichem immunschwächevirus hemmen und deren anwendungsweisen
HRP20030701A2 (en) Natural antibodies active against hiv virus